...
首页> 外文期刊>Disease models & mechanisms: DMM >Chemical enhancement of torsinA function in cell and animal models of torsion dystonia
【24h】

Chemical enhancement of torsinA function in cell and animal models of torsion dystonia

机译:化学增强torsinA功能在扭转性肌张力障碍细胞和动物模型中的作用

获取原文
           

摘要

Movement disorders represent a significant societal burden for which therapeutic options are limited and focused on treating disease symptomality. Early-onset torsion dystonia (EOTD) is one such disorder characterized by sustained and involuntary muscle contractions that frequently cause repetitive movements or abnormal postures. Transmitted in an autosomal dominant manner with reduced penetrance, EOTD is caused in most cases by the deletion of a glutamic acid (ΔE) in the DYT1 (also known as TOR1A ) gene product, torsinA. Although some patients respond well to anticholingerics, therapy is primarily limited to either neurosurgery or chemodenervation. As mutant torsinA (ΔE) expression results in decreased torsinA function, therapeutic strategies directed toward enhancement of wild-type (WT) torsinA activity in patients who are heterozygous for mutant DYT1 may restore normal cellular functionality. Here, we report results from the first-ever screen for candidate small molecule therapeutics for EOTD, using multiple activity-based readouts for torsinA function in Caenorhabditis elegans , subsequent validation in human DYT1 patient fibroblasts, and behavioral rescue in a mouse model of DYT1 dystonia. We exploited the nematode to rapidly discern chemical effectors of torsinA and identified two classes of antibiotics, quinolones and aminopenicillins, which enhance WT torsinA activity in two separate in vivo assays. Representative molecules were assayed in EOTD patient fibroblasts for improvements in torsinA-dependent secretory function, which was improved significantly by ampicillin. Furthermore, a behavioral defect associated with an EOTD mouse knock-in model was also rescued following administration of ampicillin. These combined data indicate that specific small molecules that enhance torsinA activity represent a promising new approach toward therapeutic development for EOTD, and potentially for other diseases involving the processing of mutant proteins.
机译:运动障碍代表了巨大的社会负担,对此,治疗选择受到限制,并集中于治疗疾病症状。早发性扭转肌张力障碍(EOTD)是一种此类疾病,其特征在于持续的肌肉收缩和非自愿的肌肉收缩,经常引起重复性运动或姿势异常。在大多数情况下,EOTD以常染色体显性方式传播,且渗透率降低,这是由DYT1(也称为TOR1A)基因产物TorsinA中的谷氨酸(ΔE)缺失引起的。尽管一些患者对抗胆碱药反应良好,但治疗主要限于神经外科手术或化学神经支配。由于突变型TorsA的表达(ΔE)导致TorsinA的功能降低,针对突变DYT1杂合的患者中针对野生型(WT)torsinA活性增强的治疗策略可能会恢复正常的细胞功能。在这里,我们报道了有史以来首次针对EOTD小分子治疗药物进行筛选的结果,该研究使用了基于活动性的读数来反映秀丽隐杆线虫的torsinA功能,随后在人类DYT1患者成纤维细胞中进行验证,并在DYT1肌张力障碍的小鼠模型中进行行为抢救。我们利用线虫来快速识别TorsinA的化学效应物,并鉴定出两类抗生素,喹诺酮类和氨基青霉素类,它们在两种单独的体内试验中增强了WT TorsinA的活性。在EOTD患者成纤维细胞中检测了代表性分子,以改善TorsA依赖的分泌功能,氨苄青霉素可显着改善这种功能。此外,在使用氨苄西林后,还挽救了与EOTD小鼠敲入模型相关的行为缺陷。这些综合数据表明,增强TorsA活性的特定小分子代表了有前途的新方法,可用于EOTD的治疗开发,并可能用于涉及突变蛋白加工的其他疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号